Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes Ant
Been difficult to buy for about 5 or 6 days now ( as in difficult to get quotes for 100k to 200k or goes to negotiate trade)
I am pleased to pass on various suggestions as I do but more to see that the company has matured to a point where the present management and directors can really make a difference. I expect news soon and monitor progress closely.
Ant
Would be great if you reach out directly to Peter S
In last 3mths I have had 2 queries answered promptly and Judging by his manner and enthusiasm I am sure he would be glad to talk to you ?
Can I also echo Trench123 and King h
Thankyou Ant
I have been writing an article very recently ( not published as yet) On the NHS This is an aside But clearly Dosing Regimes such as this are not only excellent news for patients but also present significant costs savings too. Drug mis-use primarily over ordering and not using cost The NHS millions each year, potential savings are enormous. So too the use of Generic Drugs which worldwide currently cost Health Service providers in excess of £400 billion a year and projected to rise to over £600 billion by 2030. The NHS has been intransigent but needs to avail itself of all the emergent technologies that diagnostic medical techniques present. As a complete aside We should also have a Government funded Generic GMP facility in the UK The savings would more than warrant its building and operation instead of making some foreign manufacturers incredibly wealthy!
I would also like to second Trench’s Post.
Ant your contribution are brilliant and very much welcomed.
I have been invested in PYC for many many many years and the personalised dosing tool as stated numerous times could / should have huge commercial value.
I could be wrong but my understanding although there is numerous way it could be rolled out if approved that the technology would be integrated to Dosemerx and PYC would get a fee for this tech per license of which DoseMe has hundreds of thousand licenses in hospitals, surgery’s, universities and practises world wide !!!
This in mind the potential is exponential before you look at the UK (NHS) and European market
Difficult to buy today?
Ant, thanks for your excellent contributions which are most interesting and welcome
PYC have been banging the drum for personalised medicine for many years. They should be well placed to take full advantage now that the industry has finally recognised its huge potential opportunities and benefits
Trench around 25 years ago Oxford University presented a personalised dosing mechanism to The Royal Society it was primarily designed to be for Diabetes Patients and intended to rely on a Grid they were developing as a secure alternative to "the internet" It was being designed to pass information and control from and to patients. My recollections are scanty save that it attracted offers of serious finance to progress and whilst afforded my offer of funding at the time was frozen out. The availability of Cloud based technology now only serves to enhance this concept. It is this type of "add on" that could really accelerate the take up of DoseMeRX . On the evidence of past experience and as above, there will be significant monies made available by Pharma Cos worldwide as they are all keen to accurately deliver correct dosing regimes on a personalised basis . It may well prove to be the gamechanger here we are all predicting. The time is now right as unlike previously, while a number of us were engaged in thoughts of Personalised medicines then it was a step to far. I don't need to wish shareholders good luck the technology that PYC have at their disposal will provide the answers!
I was a bit unsure when the company announced that it was initiating a company newsletter
However, I have been impressed by how much relevant news has been contained in the first few issues. It is a credit to the determined effort PYC are making to improve the profile of the company. Lets hope this continues in the near term with details regarding the Head of Modelling appointment, maybe an update on the G-CSF project, some important news on the Biostatistics initiative, contract announcements etc. Exciting times for those with a genuine interest